DNA methylation and miRNA expression profiling in childhood B-cell acute lymphoblastic leukemia

Epigenomics

Volumn 2, Issue 5, 2010, Pages 697-708

  Chatterton, Zac ^a,b   Morenos, Leah ^a,b   Saffery, Richard ^a,b   Craig, Jeffrey M ^a,b   Ashley, David ^c   Wong, Nicholas C ^a,b,c  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

biomarker; childhood pediatric acute lymphoblastic leukemia; DNA methylation; epigenetics; miRNA

Indexed keywords

DNA; MICRORNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER GENETICS; CHILDHOOD CANCER; DNA METHYLATION; EPIGENETICS; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOME; HUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW;

CHILD; DNA METHYLATION; EPIGENESIS, GENETIC; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICRORNAS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 78149446759     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.10.39     Document Type: Review

References (76)

1. Bird A: Perceptions of epigenetics. Nature 447(7143), 396-398 (2007).
2. Clark SJ, Harrison J, Frommer M: CpNpG methylation in mammalian cells. Nat. Genet. 10(1), 20-27 (1995).
3. Lister R, Pelizzola M, Dowen RH et al.: Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462(7271), 315-322 (2009).
4. Ramsahoye BH, Biniszkiewicz D, Lyko F, Clark V, Bird AP, Jaenisch R: Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc. Natl Acad. Sci. USA 97(10), 5237-5242 (2000).
5. Gehring M, Henikoff S: DNA methylation dynamics in plant genomes. Biochim. Biophys. Acta. 1769(5-6), 276-286 (2007).
6. Kriaucionis S, Heintz N: The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324(5929), 929-930 (2009).
7. Tahiliani M, Koh KP, Shen Y et al.: Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324(5929), 930-935 (2009).
8. Rakyan VK, Hildmann T, Novik KL et al.: DNA methylation profling of the human major histocompatibility complex: a pilot study for the human epigenome project. PLoS Biol. 2(12), e405 (2004).
9. Cheng X, Blumenthal RM: Coordinated chromatin control: structural and functional linkage of DNA and histone methylation. Biochemistry 49(14), 2999-3008 (2010).
10. Feinberg AP: A genetic approach to cancer epigenetics. Cold Spring Harb. Symp. Quant. Biol. 70, 335-341 (2005).
11. Gronbaek K, Hother C, Jones PA: Epigenetic changes in cancer. APMIS 115(10), 1039-1059 (2007).
12. Ushijima T, Asada K: Aberrant DNA methylation in contrast with mutations. Cancer Sci. 101(2), 300-305 (2010).
13. Toyota M, Ahuja N, Ohe-Toyota M, Herman G, Baylin SB, Issa JP: CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96(15), 8681-8686 (1999). (Pubitemid 29354851)
14. Issa JP: CpG island methylator phenotype in cancer. Nat. Rev. Cancer 4(12), 988-993 (2004).
15. Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH: Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch. 455(6), 485-494 (2009).
16. Li B, Liu W, Wang L et al.: CpG island methylator phenotype associated with tumor recurrence in tumor-node-metastasis stage I hepatocellular carcinoma. Ann. Surg. Oncol. 17(7), 1917-1926 (2010).
17. Cheng Y, Zhang C, Zhao J et al.: Correlation of CpG island methylator phenotype with poor prognosis in hepatocellular carcinoma. Exp. Mol. Pathol. 88(1), 112-117 (2010).
18. Sato H, Oka T, Shinnou Y et al.: Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma. Am. J. Pathol. 176(1), 402-415 (2010).
19. Tanemura A, Terando AM, Sim MS et al.: CpG island methylator phenotype predicts progression of malignant melanoma. Clin. Cancer Res. 15(5), 1801-1807 (2009).
20. Onciu M: Acute lymphoblastic leukemia. Hematol. Oncol. Clin. North Am. 23(4), 655-674 (2009).
21. Heerema-Mckenney A, Arber DA: Acute myeloid leukemia. Hematol. Oncol. Clin. North Am. 23(4), 633-654 (2009).
22. Stone RM: Prognostic factors in AML in relation to (ab)normal karyotype. Best Pract. Res. Clin. Haematol. 22(4), 523-528 (2009).
23. + leukemia therapy Best Pract. Res. Clin. Haematol. 22(3), 445-454 (2009).
24. Krug U, Ganser A, Koeffer HP: Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 21(21), 3475-3495 (2002).
25. Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N. Engl. J. Med. 350(15), 1535-1548 (2004).
26. Greaves M: In utero origins of childhood leukemia. Early Hum. Dev. 81(1), 123-129 (2005).
27. Sabaawy HE, Azuma M, Embree LJ, Tsai HJ, Starost MF, Hickstein DD: Tel-AML1 transgenic zebrafsh model of precursor B cell acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA 103(41), 15166-15171 (2006).
28. Calero Moreno TM, Gustafsson G, Garwicz S et al.: Deletion of the INK4-locus (the p16INK4a, p14arf and p15ink4b genes) predicts relapse in children with all treated according to the Nordic protocols nopho-86 and nopho-92. Leukemia 16(10), 2037-2045 (2002).
29. Maloney KW, Mcgavran L, Odom LF, Hunger SP: Acquisition of p16(ink4a) and p15(ink4b) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Blood 93(7), 2380-2385 (1999).
30. Felix CA, Nau MM, Takahashi T et al.: Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J. Clin. Invest. 89(2), 640-647 (1992).
31. Mullighan CG, Goorha S, Radtke I et al.: Genome-wide ana lysis of genetic alterations in acute lymphoblastic leukemia. Nature 446(7137), 758-764 (2007).
32. Zuo T, Tycko B, Liu TM, Lin HJ, Huang THM: Methods in DNA methylation profling. Epigenomics 1(3), 331-345 (2009).
33. Laird PW: Principles and challenges of genome-wide DNA methylation ana lysis. Nat. Rev. Genet. 11(3), 191-203 (2010).
34. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specifc PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93(18), 9821-9826 (1996).
35. Gutierrez MI, Siraj AK, Bhargava M et al.: Concurrent methylation of multiple genes in childhood ALL: Correlation with phenotype and molecular subgroup. Leukemia 17(9), 1845-1850 (2003).
36. Yang Y, Takeuchi S, Hofmann WK et al.: Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia. Leuk. Res. 30(1), 98-102 (2006).
37. Roman-Gomez J, Jimenez-Velasco A, Agirre X et al.: Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. Leukemia 20(8), 1445-1448 (2006).
38. Kim M, Yim Sh, Cho NS et al.: Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood b-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study Cancer Genet. Cytogenet. 195(1), 59-65 (2009).
39. Hesson LB, Dunwell TL, Cooper WN et al.: The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukemias. Mol. Cancer 8, 42 (2009).
40. Paulsson K, An Q, Moorman AV et al.: Methylation of tumour suppressor gene promoters in the presence and absence of transcriptional silencing in high hyperdiploid acute lymphoblastic leukemia. Br. J. Haematol. 144(6), 838-847 (2009).
41. Bock C: Epigenetic biomarker development. Epigenomics 1(1), 99-110 (2009).
42. Stumpel DJ, Schneider P, van Roon EH et al.: Specifc promoter methylation identifes different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, infuences clinical outcome, and provides therapeutic options. Blood 114(27), 5490-5498 (2009).
43. Dunwell TL, Hesson LB, Pavlova T et al.: Epigenetic ana lysis of childhood acute lymphoblastic leukemia. Epigenetics 4(3), 185-193 (2009).
44. Taylor KH, Pena-Hernandez KE, Davis JW et al.: Large-scale CpG methylation ana lysis identifes novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res. 67(6), 2617-2625 (2007).
45. Davidsson J, Lilljebjorn H, Andersson A et al.: The DNA methylome of pediatric acute lymphoblastic leukemia. Hum. Mol. Genet. 18(21), 4054-4065 (2009).
46. Dunwell T, Hesson L, Rauch TA et al.: A genome-wide screen identifes frequently methylated genes in haematological and epithelial cancers. Mol. Cancer 9, 44 (2010).
47. Schafer E, Irizarry R, Negi S et al.: Promoter hypermethylation in MLL-R infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood 115(23), 4798-4809 (2010).
48. Bibikova M, Fan JB: Goldengate assay for DNA methylation profling. Methods Mol. Biol. 507, 149-163 (2009).
49. Milani L, Lundmark A, Kiialainen A et al.: DNA methylation for subtype classifcation and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood 115(6), 1214-1225 (2010).
50. Taylor KH, Kramer RS, Davis JW et al.: Ultradeep bisulfte sequencing ana lysis of DNA methylation patterns in multiple gene promoters by 454 sequencing. Cancer Res. 67(18), 8511-8518 (2007).
51. Wang MX, Wang HY, Zhao X et al.: Molecular detection of B-cell neoplasms by specifc DNA methylation biomarkers. Int. J. Clin. Exp. Pathol. 3(3), 265-279 (2010).
52. Deneberg S, Grovdal M, Karimi M et al.: Gene-specifc and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia 24(5), 932-941 (2010).
53. Lister R, Ecker JR: Finding the ffth base: genome-wide sequencing of cytosine methylation. Genome Res. 19(6), 959-966 (2009).
54. Flusberg BA, Webster DR, Lee JH et al.: Direct detection of DNA methylation during single-molecule, real-time sequencing. Nat. Methods 7(6), 461-465 (2010).
55. Davalos V, Esteller M: miRNAs and cancer epigenetics: a macrorevolution. Curr. Opin Oncol. 22(1), 35-45 (2010).
56. Esquela-Kerscher A, Slack FJ: Oncomirs-miRNAs with a role in cancer. Nat. Rev. Cancer 6(4), 259-269 (2006).
57. Zhang H, Li Y, Lai M: The miRNA network and tumor metastasis. Oncogene 29(7), 937-948 (2010).
58. Xie L, Qian X, Liu B: miRNAs: Novel biomarkers for gastrointestinal carcinomas. Mol. Cell Biochem. 341(1-2), 291-299 (2010).
59. Seca H, Almeida GM, Guimaraes JE, Vasconcelos MH: miR signatures and the role of miRs in acute myeloid leukemia. Eur. J. Cancer 46(9), 1520-1527 (2010).
60. Volinia S, Galasso M, Costinean S et al.: Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 20(5), 589-599 (2010).
61. Schotte D, Chau JC, Sylvester G et al.: Identifcation of new miRNA genes and aberrant miRNA profles in childhood acute lymphoblastic leukemia. Leukemia 23(2), 313-322 (2009).
62. Ju X, Li D, Shi Q, Hou H, Sun N, Shen B: Differential miRNA expression in childhood B-cell precursor acute lymphoblastic leukemia. Pediatr. Hematol. Oncol. 26(1), 1-10 (2009).
63. Mi S, Lu J, Sun M et al.: miRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc. Natl Acad. Sci. USA 104(50), 19971-19976 (2007).
64. Fulci V, Colombo T, Chiaretti S et al.: Characterization of B-and T-lineage acute lymphoblastic leukemia by integrated ana lysis of microRNA and mRNA expression profles. Genes Chromosomes Cancer 48(12), 1069-1082 (2009).
65. Chen J, Odenike O, Rowley JD: Leukaemogenesis: more than mutant genes. Nat. Rev. Cancer 10(1), 23-36 (2010).
66. Friedman JM, Liang G, Liu CC et al.: The putative tumor suppressor miRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res. 69(6), 2623-2629 (2009).
67. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A et al.: Epigenetic silencing of the tumor suppressor miRNA HSA-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 69(10), 4443-4453 (2009).
68. Roman-Gomez J, Agirre X, Jimenez-Velasco A et al.: Epigenetic regulation of miRNAs in acute lymphoblastic leukemia. J. Clin. Oncol. 27(8), 1316-1322 (2009).
69. Mattick JS, Taft RJ, Faulkner GJ: A global view of genomic information-moving beyond the gene and the master regulator. Trends Genet. 26(1), 21-28 (2010).
70. Huang Y, Pastor WA, Shen Y, Tahiliani M, Liu DR, Rao A: The behaviour of 5-hydroxymethylcytosine in bisulfte sequencing. PLoS ONE 5(1), e8888 (2010).
71. Milani L, Lundmark A, Nordlund J et al.: Allele-specifc gene expression patterns in primary leukemic cells reveal regulation of gene expression by CpG site methylation. Genome Res. 19(1), 1-11 (2009).
72. Strathdee G, Holyoake TL, Sim A et al.: Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin. Cancer Res. 13(17), 5048-5055 (2007).
73. Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J: The role of miRNAs in normal and malignant hematopoiesis. Eur. J. Haematol. 84(1), 1-16 (2010).
74. Li X, Liu J, Zhou R, Huang S, Chen XM: Gene silencing of miR22 in acute lymphoblastic leukemia involves histone modifcations independent of promoter DNA methylation. Br. J. Haematol. 148(1), 69-79 (2010).
75. Zanette DL, Rivadavia F, Molfetta GA et al.: miRNA expression profles in chronic lymphocytic and acute lymphocytic leukemia. Braz. J. Med. Biol. Res. 40(11), 1435-1440 (2007).
76. Bandyopadhyay S, Mitra R, Maulik U, Zhang MQ: Development of the human cancer miRNA network. Silence 1(1), 6 (2010).